Jovan P Antovic

Karolinska University Hospital, Tukholma, Stockholm, Sweden

Are you Jovan P Antovic?

Claim your profile

Publications (55)144.03 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Direct oral anticoagulant dabigatran was first introduced as a fixed-dose drug without routine coagulation monitoring, but current recommendations suggest that diluted thrombin time can be used to estimate plasma drug level. The aim of this study was to assess a diluted thrombin time assay based on the same thrombin reagent already used for traditional thrombin time measurements that reliably measure low to intermediate plasma dabigatran levels. Methods: We included 44 patients with atrial fibrillation who started treatment with dabigatran 150 mg (23 patients) or 110 mg (21 patients) twice a day. Blood samples were collected at baseline (no dabigatran) and 2-4 weeks after the beginning of dabigatran therapy at trough and at peak. Plasma dabigatran levels were measured with diluted thrombin time and compared to liquid chromatography with tandem mass spectrometry as the reference method. The performance of the diluted thrombin time was compared to Hemoclot® Thrombin Inhibitor and Ecarin Chromogenic Assay. Results: In ex vivo plasma samples, diluted thrombin time highly correlated with the liquid chromatography with tandem mass spectrometry (Pearson's R = 0.9799). In the low to intermediate range (dabigatran concentration ≤ 100 µg/L) diluted thrombin time correlated significantly more closely to the liquid chromatography with tandem mass spectrometry (R = 0.964) than Hemoclot® Thrombin Inhibitor (R = 0.935, p = 0.05) or Ecarin Chromogenic Assay (R = 0.915, p < 0.01). It was also the only functional assay without any significant bias in the low to intermediate range. Both trough and peak diluted thrombin time values were similar to liquid chromatography with tandem mass spectrometry. Conclusion: We conclude that the diluted thrombin time assay presented in this study reliably detects dabigatran and that it is superior to the Hemoclot® Thrombin Inhibitor assay in the low to intermediate range.
    Annals of Clinical Biochemistry 09/2015; DOI:10.1177/0004563215599795 · 2.34 Impact Factor

  • Annals of the Rheumatic Diseases 06/2015; 74(Suppl 2):642.3-643. DOI:10.1136/annrheumdis-2015-eular.5847 · 10.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Routine laboratory monitoring is currently not recommended in patients receiving dabigatran despite its considerable variation in plasma concentration. However, in certain clinical situations, measurements of the dabigatran effect may be desirable. We aimed to assess the variability of dabigatran trough and peak concentration and explore the potential relationship between dabigatran concentration and adverse events. We included 44 patients with atrial fibrillation who started treatment with dabigatran 150 mg (D150) or 110 mg (D110) twice daily. They contributed 170 trough and peak blood samples that were collected 2-4 and 6-8 weeks after dabigatran initiation. Plasma dabigatran concentration was measured by LC-MS/MS and indirectly, by selected coagulation tests. D110 patients were older (74±7 versus 68±6 years), had lower creatinine clearance (68±21 versus 92±24 mL/min) and higher CHA2 DS2 -VASc score (3.1±1.3 versus 2.3±0.9) compared to D150 patients (all p<0.05), but both had similar dabigatran concentrations in both trough and peak samples. Dabigatran concentrations varied less in trough than in peak samples (17.0±13.6 versus 26.6±19.2 %, p=0.02). During the 12-month follow-up, 4 patients on D150 and 6 on D110 suffered minor bleeding. There was no major bleeding or thromboembolic event. Patients with bleeding had significantly higher average trough dabigatran concentrations (93±36 versus 72±62 μg/L, p=0.02) than patients without bleeding, while peak dabigatran values had no predictive value. Dabigatran dose selection according to the guidelines resulted in appropriate trough concentrations with acceptable repeatability. High trough concentrations may predispose patients to the risk of minor bleeding. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Basic & Clinical Pharmacology & Toxicology 05/2015; 117(5). DOI:10.1111/bcpt.12417 · 2.38 Impact Factor
  • L. Onelöv · R. Basmaji · A. Svensson · M. Nilsson · J. P. Antovic ·
    [Show abstract] [Hide abstract]
    ABSTRACT: IntroductionFrequent PT (INR) testing may represent a problem for patients on warfarin treatment, and capillary or small-volume tubes may be more appropriate for such patients. A demand for small-volume tubes also comes from pediatric wards. Yet, while various small-volume tubes are available, they have not been properly evaluated.Methods Three small-volume tubes were tested (MiniCollect 3.8% citrate, MiniCollect 3.2% citrate and Microvette EDTA) and compared with a standard 4.5-mL 3.2% citrated tube. Samples were taken by venipuncture from the back of the hand and by capillary sampling from the tip of the finger. The measures were compared with those after standard venipuncture of the arm fold. A total of 180 samples, using different combinations of tubes and sampling sites, were collected from 30 volunteers.ResultsThere were no differences in the results obtained using citrate tubes for venous samples in comparison with those obtained by standard sampling, while the results when using EDTA tubes were not comparable to those obtained by standard sampling (P < 0.001), expressing systematically lower values (by about 10%). The results observed after capillary sampling were significantly different to those obtained after standard sampling.Conclusions The MiniCollect 3.2% tube may be used for PT (INR) venipuncture samples when withdrawal of a small amount of blood is preferable, while EDTA tubes should not be used for PT (INR) testing.
    International journal of laboratory hematology 05/2015; 37(5). DOI:10.1111/ijlh.12387 · 1.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The direct factor-Xa inhibitor apixaban is approved e.g. for the prevention of stroke in patients with atrial fibrillation (AF). Although routine monitoring of apixaban therapy is currently not recommended, selective monitoring could be useful to optimize efficacy and safety in certain clinical situations. We studied the exposure and effect of apixaban using different laboratory methods in a clinical setting with a well-defined cohort of AF patients. Seventy AF patients (72±7.4years, 64 % men, mean CHADS2 score 1.7) treated with apixaban 2.5 (n=10) or 5mg BID (n=60). Trough plasma apixaban concentrations determined by liquid chromatography-tandem mass-spectrometry (LC-MS/MS) were compared to the coagulation assays Anti-factor Xa, PT-INR and aPTT. The apixaban plasma concentration determined by LC-MS/MS varied more than 10-fold overall. The range was between 15-83 and 29-186ng/mL for the 2.5mg BID and 5mg BID respectively, with patients receiving 5mg BID having significantly higher apixaban concentrations (p<0.001). A strong correlation between LC-MS/MS and anti-FXa-assay was found (p<0.001), while aPTT and PT-INR were not sensitive enough. There were no significant correlations between gender, creatinine clearance, body weight or age and apixaban exposure. Anti-FXa-assay performed well upon apixaban concentrations in a normal exposure range. Still LC-MS/MS remains the "gold standard" method, covering also low concentrations. Compared to clinical trials, we observed relatively lower apixaban exposure and a more pronounced difference between high and low dose. Additional information regarding apixaban exposure and benefit-risk profile is needed in order to individualize treatment. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Thrombosis Research 04/2015; 136(1). DOI:10.1016/j.thromres.2015.04.030 · 2.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction The oral direct thrombin inhibitor dabigatran is increasingly used to prevent thromboembolic stroke in patients with atrial fibrillation (AF). Routine laboratory monitoring is currently not recommended, but measurements of dabigatran and/or its effect are desirable in certain situations. We studied dabigatran exposure and compared different tests for monitoring of dabigatran in a real-life cohort of AF patients. Material and methods Ninety AF patients (68 ± 9 years, 67% men, mean CHADS2 score 1.5) were treated with dabigatran 150 (n = 73) or 110 mg BID (n = 17). Trough plasma concentrations of total and free dabigatran by liquid chromatography-tandem mass-spectrometry (LC-MS/MS) were compared to indirect measurements by Hemoclot thrombin inhibitors (HTI) and Ecarin clotting assay (ECA), as well as PT-INR and aPTT. Results Total plasma dabigatran varied 20-fold (12–237 ng/mL with 150 mg BID) and correlated well with free dabigatran (r2 = 0.93). There were strong correlations between LC-MS/MS and HTI or ECA (p < 0.001) but these assays were less accurate with dabigatran below 50 ng/mL. The aPTT assay was not dependable and PT-INR not useful at all. There were weak correlations between creatinine clearance (Cockcroft-Gault) and LC-MS/MS, HTI and ECA (p < 0.001 for all). A high body weight with normal kidney function was associated with low dabigatran levels. Conclusions HTI and ECA reflect the intensity of dabigatran anticoagulation, but LC-MS/MS is required to quantify low levels or infer absence of dabigatran. Most real life patients with a normal creatinine clearance had low dabigatran levels suggesting a low risk of bleeding but possibly limited protection against stroke.
    Thrombosis Research 10/2014; 134(4). DOI:10.1016/j.thromres.2014.06.016 · 2.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with haemophilia A have seriously impaired thrombin generation due to an inherited deficiency of factor (F)VIII, making them form unstable fibrin clots that are unable to maintain haemostasis. Data on fibrin structure in haemophilia patients remain limited. Fibrin permeability, assessed by a flow measurement technique, was investigated in plasma from 20 patients with severe haemophilia A treated on demand, before and 30 minutes after FVIII injection. The results were correlated with concentrations of fibrinogen, FVIII and thrombin-activatable fibrinolysis inhibitor (TAFI), and global haemostatic markers: endogenous thrombin potential (ETP) and overall haemostatic potential (OHP). Fibrin structure was visualized using scanning electron microscopy (SEM). The permeability coefficient Ks decreased significantly after FVIII treatment. Ks correlated significantly with FVIII levels and dosage, and with ETP, OHP and levels of TAFI. SEM images revealed irregular, porous fibrin clots composed of thick and short fibers before FVIII treatment. The clots had recovered after FVIII replacement almost to levels in control samples, revealing compact fibrin with smaller intrinsic pores. To the best of our knowledge, this is the first description of fibrin porosity and structure before and after FVIII treatment of selected haemophilia patients. It seems that thrombin generation is the main determinant of fibrin structure in haemophilic plasma.
    Thrombosis and Haemostasis 11/2013; 111(4). DOI:10.1160/TH13-06-0479 · 4.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Increased thrombin generation, as measured by the Calibrated Automated Thrombogram (CAT), has recently been reported to predict ischemic stroke, especially stroke with a cardioembolic source. However, there are few studies on thrombin generation using CAT in patients with manifest ischemic stroke, particularly in patients with cardioembolic stroke not yet on anticoagulation. Materials and methods: Therefore, a prospective cohort study of 205 stroke patients > 45 years of age was performed. They were recruited during their hospital stay or shortly thereafter. Inclusion criteria were ischemic stroke or TIA within two weeks and no atrial fibrillation (AF) in the history or at inclusion. Patients received a thumb ECG device in order to detect silent AF. Blood samples were collected at inclusion and after 1 month. Thrombin generation in plasma after addition of tissue factor was assessed in patients and in healthy controls. Results: Mean age of patients was 72 ± 7 years and 43% were females. Peak thrombin concentrations were variable among stroke patients but overall significantly higher at both time points (p < 0.0001) compared to controls, and tended to be highest in patients in whom paroxysmal atrial fibrillation was subsequently documented. Conclusion: Thrombin generation in patients with acute cardioembolic and non-cardioembolic schemic stroke/TIA is variable but overall higher compared to healthy subjects. The long-term prognostic value of thrombin generation in patients with a recent ischemic stroke deserves further investigation.
    Scandinavian journal of clinical and laboratory investigation 09/2013; 73(7). DOI:10.3109/00365513.2013.826817 · 1.90 Impact Factor
  • E Westerlund · B J Woodhams · J Eintrei · L Söderblom · J P Antovic ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The soluble fibrin monomer (sFM) assay, like the D-dimer (DDi) assay, has the potential to be used both as an aid in the diagnosis of disseminated intravascular coagulation (DIC) and as a thrombotic marker. It differs from DDi in that it is a much earlier produced fragment produced only by thrombin action on fibrinogen, whereas DDi is a much later produced fragment formed by plasmin cleavage of cross-linked fibrin. In our study, we compared two commercially available automated sFM assays in the routine hospital setting using samples obtained from the general hospital ward and the emergency room. The results obtained with the two automated assays (Stago LIA sFM assays and the LPIA-Iatro SF assay) were compared with each other and with the results obtained using the routine semiquantitative hemagglutination assay. The study showed that both automated assays were comparable with each other. No patient sample previously classified as positive would be missed, but with the higher sensitivity in the automated tests, more samples are positive. In conclusion, we suggest that both automated tests are suitable for routine laboratory use. Both assays had the advantage over the hemagglutination assay in that previously frozen samples could be used, and the assays are easier and quicker to perform. The LIA sFM Stago has slightly better sensitivity but has a tendency to lower specificity than the Iatro SF test.
    International journal of laboratory hematology 06/2013; 35(6). DOI:10.1111/ijlh.12117 · 1.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Dabigatran is an oral direct thrombin inhibitor for which routine laboratory monitoring is currently not recommended. However, there are situations in which measurements of the drug and its effect are desirable. We therefore compared and validated different coagulation methods for assessments of dabigatran in clinical samples in relation to measurements of plasma dabigatran, without the purpose of establishing effective and safe concentrations of dabigatran in plasma. Methods: Samples were obtained from 70 atrial fibrillation patients treated with dabigatran etexilate. Plasma concentrations were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and were compared with coagulation methods Hemoclot thrombin inhibitors (HTI) and Ecarin clotting assay (ECA), as well as with prothrombin time-international normalized ratio (PT-INR) and activated partial thromboplastin time (aPTT). Results: A wide range of dabigatran concentrations was determined by LC-MS/MS (<0.5-586 ng/mL). Correlations between LC-MS/MS results and estimated concentrations were excellent for both HTI and ECA overall (r(2) = 0.97 and 0.96 respectively, p < 0.0001), but the precision and variability of these assays were not fully satisfactory in the low range of dabigatran plasma concentrations, in which ECA performed better than HTI. aPTT performed poorly, and was normal (<40 s) even with dabigatran levels of 60 ng/mL. PT-INR was normal even at supratherapeutic dabigatran concentrations. Conclusion: LC-MS/MS is the gold standard for measurements of dabigatran in plasma. Alternatively, either HTI or ECA assays may be used, but neither of these assays is dependable when monitoring low levels or to infer total absence of dabigatran. The aPTT assay is relatively insensitive to dabigatran, and normal aPTT results may be observed even with therapeutic dabigatran concentrations.
    European Journal of Clinical Pharmacology 06/2013; 69(11). DOI:10.1007/s00228-013-1550-4 · 2.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple electrode aggregometry (MEA) is used to measure platelet function. Pneumatic tube transport systems (PTS) for delivery of patient samples to a central laboratory are often used to reduce turnaround time for vital analyses. We evaluated the effects of PTS transport on platelet function as measured by MEA. Duplicate samples were collected from 58 individuals. One sample was sent using PTS and the other was carried by personnel to the lab. Platelet function was measured by means of a Multiplate® analyzer using the ADP test, ASPI test, COL test, RISTO test and TRAP test. Samples transported using PTS showed a reduction of AUC-values of up to a 100% of the average as compared to samples carried by personnel and a majority showed reductions of AUC-values greater than 20% of the average. Bias±95% limits of agreement for the ADP test were 26±56% of the average. Bias±95% limits of agreement for the ASPI test were 16±58% of the average. Bias±95% limits of agreement for the COL test were 20±54% of the average. Bias±95% limits of agreement for the RISTO were 14±79% of the average. Bias±95% limits of agreement for the TRAP test were 19±45% of the average. We conclude that PTS transport affect platelet activity as measured by MEA. We advise against clinical decisions regarding platelet function on the basis of samples sent by PTS in our hospital settings.
    Thrombosis Research 05/2013; 132(1). DOI:10.1016/j.thromres.2013.04.020 · 2.45 Impact Factor
  • Jovan P. Antovic · Liselotte Onelöv · Nils Egberg ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Laboratory investigations are an inevitable part of diagnosis of hemostatic disturbances. Screening analyses are usually performed in general clinical chemistry laboratories and are available 24 hours. They include platelet counts, PT(INR), aPTT, levels of fibrinogen, D-dimer, and antithrombin. More detailed investigation of coagulation abnormalities is reserved for special coagulation laboratories and includes determination of single coagulation factors (FII, FV, FVII, FVIII, FIX, FX, FXI, FXII, FXIII); anticoagulants (antibodies against coagulation factors (particularly FVIII and FIX), and lupus anticoagulant); coagulation inhibitors (PS, PS); fibrinolysis factors (plasminogen, t-PA) and inhibitors (plasmin inhibitor, PAI-1) and functional platelet analyses. Additional analyses of markers of coagulation activation and global hemostatic assays may also be performed. Genetic investigations are primarily aimed at detection of mutation in genes for FVIII, FIX and VWF, and polymorphisms associated with thrombophilia (prothrombin mutation and FV Leiden mutation). To help clinicians choose appropriate tests in the diagnosis of hemostatic abnormalities several investigation “packages” may be offered (bleeding tendency, venous thrombosis, arterial thrombosis, hereditary thrombophilia).
    Essential Guide to Blood Coagulation, 03/2013: pages 11-38; , ISBN: 9781118288795
  • Jovan P. Antovic · Margareta Holmström ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome are serious medical conditions associated with hemostasis activation that require rapid diagnosis and treatment, which are discussed in this chapter. Heparin-induced thrombocytopenia (HIT) is a rare but serious condition where diagnosis is based on a clinical score and laboratory findings while alternatives to heparin (i.e. argatroban, danaparoid) should be used for the treatment.
    Essential Guide to Blood Coagulation, 03/2013: pages 182-190; , ISBN: 9781118288795
  • [Show abstract] [Hide abstract]
    ABSTRACT: Obesity is a known risk factor for venous and arterial thrombosis but the mechanisms are still unclear. In women, obesity is correlated with low-grade inflammation and recent data show that BMI is positively associated with thrombin generation. We explored the correlations between obesity, inflammation and thrombin generation in women with increased thrombotic risk by looking at a cohort of women with prior venous thrombosis. One hundred and fifty-six women age 18-65 years were enrolled at diagnosis of first venous thromboembolism (VTE). Plasma samples were obtained at least 3 weeks after cessation of anticoagulant treatment. Thrombin generation was determined with the calibrated automated thrombography (CAT) assay and the Innovance ETP assay. Thrombin generation started later but was more pronounced with higher endogenous thrombin generation potential (ETP) determined with CAT in patients with obesity. The Innovance ETP assay showed results consistent with CAT. Furthermore, patients with obesity had significantly higher levels of fibrinogen, C-reactive protein and plasminogen activator inhibitor-I (PAI-I) than patients without obesity. Increased levels of fibrinogen were the main determinant of the prolonged lag-time in patients with obesity whereas higher levels of prothrombin could account for the difference in the ETP between the groups. We found an association between BMI and ETP values using two different methods to measure thrombin generation. Obesity correlated with increased thrombin generation in women with VTE and the main determinants of this hypercoagulable state were increased levels of fibrinogen and prothrombin. This shows a possible link between obesity, low-grade inflammation and increased thrombin generation in women at increased risk for future thrombosis.
    Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis 03/2013; 24(5). DOI:10.1097/MBC.0b013e32835f93d5 · 1.40 Impact Factor
  • S. Djukic · N. Andjelkovic · A. Djukic · J.P. Antovic ·

    Thrombosis Research 01/2013; 131:S82. DOI:10.1016/S0049-3848(13)70067-7 · 2.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Microparticles (MPs) are small membrane vesicles (0.1-1 μm) released from various cells after activation and/or apoptosis. There are limited data about their role in hemophilia A. Patients and methods: Blood samples were taken before and 30 min after FVIII injection in 18 patients with severe hemophilia A treated on demand. Flow-cytometric determination of total MPs (TMPs) using lactadherin, platelet MPs (PMPs) (CD42a), endothelial MPs (EMPs) (CD144) and leukocyte MPs (LMPs) (CD45) was performed. The results were compared with data on endogenous thrombin potential (ETP), overall hemostatic potential (OHP), fibrin gel permeability and thrombin-activatable fibrinolysis inhibitor (TAFI). Results and conclusions: TMPs and PMPs decreased after treatment (to 1015 ± 221 [SEM] and 602 ± 134 × 10(6) L(-1) ) in comparison with values before treatment (2373 ± 618 and 1316 ± 331; P < 0.01). EMPs also decreased after treatment (78 ± 12 vs. 107 ± 13; P < 0.05) while LMPs were not influenced. Both TMP and PMP counts were inversely correlated, moderately but statistically significantly, with data on OHP, ETP, fibrin network permeability and TAFI/TAFIi (P < 0.05 for all). EMP counts were correlated only with ETP (P < 0.05), while LMP counts did not show any correlation. TMP and PMP counts were also inversely correlated with FVIII levels (P < 0.05). TMP, PMP and EMP counts decreased after on-demand treatment with FVIII concentrate in hemophilia A patients. The decrease in circulating MPs, which were inversely correlated with hemostatic activation, may imply that MPs are incorporated in the hemostatic plug formed after FVIII substitution at the site of injury.
    Journal of Thrombosis and Haemostasis 12/2012; 11(4). DOI:10.1111/jth.12103 · 5.72 Impact Factor
  • Eli Westerlund · Jaak Eintrei · Lisbeth Söderblom · Jovan P. Antovic ·

    Thrombosis Research 10/2012; 130:S106. DOI:10.1016/j.thromres.2012.08.018 · 2.45 Impact Factor

  • Thrombosis Research 10/2012; 130:S116. DOI:10.1016/j.thromres.2012.08.043 · 2.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Haemophilia A patients with similar levels of factor VIII (FVIII) may have different bleeding phenotypes and responses to treatment with FVIII concentrate. Therefore, a test which determines overall haemostasis may be appropriate for treatment monitoring in some patients. We studied two global haemostatic methods:endogenous thrombin potential (ETP) and overall haemostatic potential(OHP) before and after injection of FVIII concentrate in patients with haemophilia A treated prophylactically and on-demand. A significant correlation between FVIII and both ETP and OHP was observed, while ETP and OHP differed between patients with severe and mild clinical phenotypes. Both ETP and OHP differed significantly between severe, moderate and mild haemophilia A and controls. ETP and OHP increased after intravenous injection of FVIII concentrate in both groups of patients, but in spite of higher pre-treatment values of both ETP and OHP in patients treated prophylactically, and much higher post-treatment FVIII levels in comparison with the values in patients treated on-demand, no difference after treatment was observed for either ETP or OHP. ETP and OHP may be additional alternatives for monitoring (and even for individual tailoring) treatment in patients with haemophilia A.
    Thrombosis and Haemostasis 04/2012; 108(1):21-31. DOI:10.1160/TH11-11-0811 · 4.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: D-dimer (DD) assays are effective for the exclusion of deep-vein thrombosis (DVT), but point-of-care (POC) DD assays have not been fully evaluated. We have compared five POC DD assays (Pathfast, Cardiac, Vidas, Stratus and NycoCard) with our routine DD method (Tinaquant), testing 60 samples from patients with suspected DVT. Using 0.5 μg/mL as a cut-off value, four samples tested negative with Tinaquant were positive with Pathfast. There were no Tinaquant-positive samples tested negative with Pathfast, while the overall agreement (k = 0.81) was very good. Four samples were discrepant between Tinaquant and Cardiac (cut-off, 0.4 μg/mL), while k = 0.72. One of two Tinaquant-negative samples was shown to be positive for either Vidas (cut-off, 0.5 μg/mL) or Stratus (cut-off, 0.4 μg/mL), respectively. The agreement with Tinaquant was excellent for both Vidas (k = 0.92) and Stratus (k = 0.94). Total CV was <10% for all four assays. Eight samples (of 27) were negative with NycoCard although they were positive with Tinaquant, while CV was 41%. Vidas cannot be considered a POC assay because the sample has to be centrifuged before testing. Our findings have also shown that the use of NycoCard is inappropriate. Stratus and Pathfast have a similar analytical profile in comparison with the Tinaquant method. Cardiac is potentially less sensitive but may still be acceptable for use. It seems that the employment of these three assays for rapid bed-side analysis offers a possibility to adequately rule out DVT in outpatients within minutes after admission.
    International journal of laboratory hematology 04/2012; 34(5):495-501. DOI:10.1111/j.1751-553X.2012.01421.x · 1.82 Impact Factor

Publication Stats

396 Citations
144.03 Total Impact Points


  • 2001-2015
    • Karolinska University Hospital
      • • Department of Clinical Chemistry
      • • Department of Hematology
      Tukholma, Stockholm, Sweden
  • 2003-2013
    • Karolinska Institutet
      • • Department of Clinical Sciences, Danderyd Hospital
      • • Department of Molecular Medicine and Surgery
      Solna, Stockholm, Sweden
  • 1993
    • University of Niš
      • Department of Biochemistry
      Niš, Serbia